A research study centered on Canada’s use of magic mushrooms revealed that almost 80% of participants are in favor of using psilocybin as a medical treatment for distressed patients. Similarly, around two-thirds of the Canadian participants support the idea of making psilocybin legally accessible for those in need.
Furthermore, an impressive 84.8 percent of participants think it would be beneficial if the public health system could cover the costs of such treatments. A large number of Canadians see psilocybin as a viable treatment option, particularly for alleviating distress at the end of life.
[toc]
Key Takeaways:
- Inhabitants of Québec, Ontario, Alberta, and British Columbia view psilocybin as a legitimate medical solution for managing existential distress at the end of life.
- Magic mushrooms are deemed safe for treating existential distress.
- Participants in two double-blind studies experienced immediate and long-lasting benefits, with effects persisting for six months or more.
Exploring Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals confront their own mortality. Patients may grapple with feelings of helplessness, isolation, anxiety, and a loss of purpose and meaning. This form of distress is particularly prevalent among patients with life-threatening conditions, often inducing thoughts of hastened death or suicide.
Generally, individuals facing terminal illnesses or significant life changes are the ones who most frequently experience this type of distress. It severely impacts their mental health and overall life quality.
Existential therapy aims to help individuals struggling with issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, feelings of purposelessness, and existential fear. However, this therapy might require multiple sessions and might not work effectively for everyone.
The uncertainty of the effectiveness of such therapy often leads individuals to seek alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Option
Over the last two decades, preliminary clinical trials have highlighted the possible advantages of psychedelic substances in treating complex mental disorders. Specifically, psilocybin has demonstrated its ability to quickly and lastingly relieve existential anxiety in patients approaching the end of their lives.
Recognizing the potential effectiveness of these proposed hallucinogenic mushrooms, especially when conventional treatments are not successful, Health Canada revised the Special Access Program in 2022. This revision permits healthcare practitioners to request controlled substances for their patients.
Canadian Endorsement for Psilocybin Access
A research article presented in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of respondents had previous experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical option for managing end-of-life existential anxiety. 63.3% believe psilocybin should be integrated into medical treatment. 84.8% advocate for this therapy to be provided by the public health system. 44.2% think healthcare practitioners should administer the substance even without Health Canada’s supervision. |
These findings align with surveys conducted in Canada, England, and Australia. The researchers accentuated that their study is distinct as it focuses on the use of psychoactive substances to manage existential anxiety in end-of-life situations.
Reasons for Canadian Advocacy of Psilocybin Use
An increasing number of Canadians are supporting the application of psilocybin for treatment, largely due to evidence from esteemed research institutions. Another influencing factor is the perceived safety of psilocybin mushrooms in relieving existential anxiety. Participants across different studies have not reported severe adverse health effects like multi-organ failure.
| Study | Approach | Results |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and persistent |
| The benefits of this therapy can last up to six months or even longer. The therapy’s effectiveness is largely due to mystical experiences that instill a sense of unity and emotional insights of great depth. | ||
| Trial at New York University | A group of 29 patients was randomly selected to receive either psilocybin or the active placebo, niacin. | The results of the study were similar to those of the Johns Hopkins study. Participants who received psilocybin reported a relief in psychological distress and a renewed perspective on life and death. |
| BMC Palliative Care | Nineteen participants, including 7 doctors, 4 nurses actively working, 4 chaplains, 3 social workers, and a psychologist, were interviewed. The aim of the study was to gain an understanding of how professionals in palliative care perceive existential distress and their views on psychedelic therapy as a treatment option. | As per the palliative care practitioners, psychedelic-assisted therapy (PAT) appears to have potential in reducing existential distress. |
Patient Experiences
The effectiveness of psilocybin is not only supported by scientific studies but also by a number of patient narratives. These accounts highlight its potential to improve mental wellbeing and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a patient diagnosed with stage 4 pancreatic cancer, describes a transformative experience during her assisted therapy. She envisioned herself on a raft, surrounded by nature, and accompanied by fantastical creatures. This vision instilled in her a profound sense of the universe’s interconnectedness and support, bringing her great peace and affirmation.
Despite receiving conventional mental health support, Yokoi continued to struggle with severe anxiety and distress following her diagnosis. Psilocybin therapy helped her reconnect with her body and provided a tangible sense of love and support. This significantly improved her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare at the time of the study and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in her levels of anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs since her therapy session, she indicated that the experiences had brought a sense of reality and meaning to her beliefs.
The Experience of Brenda
Brenda, a woman in her mid-sixties, was diagnosed with stage I colon cancer. She had never used hallucinogens, and during her medical evaluation, she was found to meet the criteria for Chronic Adjustment Disorder with associated anxiety.
In the course of her therapy, Brenda had two near-death experiences. These experiences transformed her perception of death into something she now views as a beautiful part of life’s cycle. She credited her participation in the study as the catalyst for her healing journey from childhood trauma. This profound transformation was reflected in her data, with reduced fear of death and anxiety, complemented by an increase in her spirituality.
Availability of Magic Mushroom Products in Canada
At present, the access to psilocybin capsules and other products designed for managing existential distress or mental health disorders could be limited. Nonetheless, reliable online dispensaries serve as a viable source for these products when needed.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and certain South American countries nearby. | Discovered in Cambodia, particularly around the Angkor Wat Temple. | Associated with the Penis Envy mushrooms, which became popular in the 1970s. |
| Strength | Moderately potent, suitable for novices. | Moderate potency as well, ideal for beginners. | Highly potent, suggested for those with a medium to high level of experience. |
| Effects | Results in a mental buzz, mild disorientation, enhanced color perception, euphoria, spiritual experiences, amplified creativity, and increased focus. | Induces an energizing, enduring high, minor visual changes, enhanced creativity, euphoria, a gentle physical high, fractal imagery, and feelings of joy. | Leads to profound shamanic experiences, vision quests, intense mystical experiences, elevated creativity, focus, social awareness, and mood enhancement. |
Mitigate End-of-life Distress with Psilocybin Products
Existential or end-of-life distress can impose significant burdens on patients nearing the end of their lives. Conventional treatments may not always provide relief, fueling a growing demand for easier access to magic mushrooms within public healthcare in Canada. This uptick in public interest could We advocate for regulatory authorities to recognize the potential of magic mushrooms as a credible treatment option. Obtain your psychedelics and mushroom delivery from Magic Mushrooms Calgary Canada.
Frequently Asked Questions
What should patients expect during Psilocybin-Assisted Therapy?
Psychedelic-assisted therapy (PAT) experiences can significantly differ amongst patients, and ensuring positive outcomes requires careful preparation and strict adherence to specific procedures. Patients must go through comprehensive screening and mental readiness before taking the substance.
- Preparation Phase: A thorough evaluation is conducted for patients. The therapist discusses the patient’s goals and expectations to set intentions for the therapy session. The therapist also explains the effects of the process and what the patients should expect during the session.
- The Therapy Session: Patients receive a controlled dosage of the substance in a comfortable, distraction-free environment to promote relaxation and self-reflection. The therapist is present throughout, providing ongoing support and guidance.
- Post-Session Integration Therapy: This therapy helps the patient understand and interpret their experiences. Further sessions provide continued support and counselling to reinforce the insights and transformations gained during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by attaching to serotonin receptors, primarily the 5-HT2A receptor. This interaction can cause changes in perception, mood, and cognition, leading to significant alterations in consciousness, emotional breakthroughs, and new perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t appropriate for everyone. Patients with certain mental health conditions or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Articles:
